AI drug discovery is judged by workflow, not just novelty

What happened

Biotech partnerships are increasingly focused on measurable improvements in candidate selection, experimental design, and the movement from discovery into clinical development.

Why it matters

The important question is whether AI reduces failed experiments and shortens the path to a safe candidate. That creates a more concrete test for the technology's return on R&D spending.